Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

Celltex To Initiate New Clinical Program As It Responds To FDA Letter 

October 1, 2012 - (The Sacramento Bee) - "Celltex Therapeutics Corp. announced today that it has received a letter, dated Sept. 24, 2012, from the U.S. Food and Drug Administration. The letter stated the agency's opinion that the process Celltex uses to multiply adult stem cells is subject to FDA regulation as biological drug manufacturing."  Read Full Article


Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: